GNPX News and Press, Genprex Inc. From 05/19/22

Genprex to Present at Upcoming Investor Conference in May 2022 PR Newswire Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 19, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "C...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has announced that chief medical officer Mark Berger, MD, will be participating the upcoming Cancer Progress Conference. The conference, which ...

Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference PR Newswire Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in so...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has issued a shareholder letter and corporate update outlining the company’s recent progress in its clinical ...

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update PR Newswire Company achieves major milestones in clinical development programs in 2022 Patient treatment in Acclaim-2 clinical trial commences AUSTIN, Texas , May 5, 2022 ...

Genprex (GNPX) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, and management will be involved in two upcoming conferences. GNPX presenters will include chief financial officer Ryan Confer and chief medical...

Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022 PR Newswire Presentations to highlight the Company's gene therapies for cancer and diabetes AUSTIN, Texas , April 18, 2022 /PRNewswire/ -- Genprex, Inc. ("G...

Shares of Genprex Inc. (NASDAQ:GNPX) traded today at $19.30, eclipsing its 52-week high. So far today approximately 165.6 million shares have been exchanged, as compared to an average 30-day volume of 390,000 shares. Genprex Inc. has overhead space with shares priced $2.09, or 2.0% below...

Genprex CFO Ryan Confer provides a preview of their upcoming presentation at NobleCon18 NobleCon18 - Noble Capital Markets 18th Annual Small and Microcap Investor Conference - April 19-21, 2022 - Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentat...